1. Home
  2. ALX vs ANIP Comparison

ALX vs ANIP Comparison

Compare ALX & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alexander's Inc.

ALX

Alexander's Inc.

HOLD

Current Price

$245.41

Market Cap

1.1B

Sector

Real Estate

ML Signal

HOLD

ANIP

ANI Pharmaceuticals Inc.

HOLD

Current Price

$70.41

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALX
ANIP
Founded
1928
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.7B
IPO Year
1994
1999

Fundamental Metrics

Financial Performance
Metric
ALX
ANIP
Price
$245.41
$70.41
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$107.33
AVG Volume (30 Days)
57.8K
324.8K
Earning Date
01-01-0001
05-11-2026
Dividend Yield
7.33%
N/A
EPS Growth
N/A
419.23
EPS
5.50
3.32
Revenue
$213,183,000.00
$206,547,000.00
Revenue This Year
N/A
$19.88
Revenue Next Year
N/A
$15.77
P/E Ratio
$44.59
$21.84
Revenue Growth
N/A
2.47
52 Week Low
$189.05
$56.71
52 Week High
$260.84
$99.50

Technical Indicators

Market Signals
Indicator
ALX
ANIP
Relative Strength Index (RSI) 53.62 33.13
Support Level $229.26 $62.89
Resistance Level $247.85 $85.12
Average True Range (ATR) 7.80 2.72
MACD 0.66 -0.26
Stochastic Oscillator 59.61 2.65

Price Performance

Historical Comparison
ALX
ANIP

About ALX Alexander's Inc.

Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Share on Social Networks: